
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana has increased its 2025 earnings per share (EPS) estimate to $17.06, reflecting strong second-quarter results and revised guidance, signaling positive financial momentum. The company's focus on margin improvement initiatives is expected to drive year-over-year earnings growth in 2027, despite assumptions regarding static performance in its Stars rating system. Furthermore, Humana's competitive advantage is bolstered by its above-industry Medicare Advantage star ratings, positioning the firm favorably amid potential regulatory and reimbursement changes.
Bears say
Humana's financial outlook is negatively impacted by expectations of a slight decline in 2026 earnings per share (EPS) compared to 2025, primarily due to challenges related to its Medicare Advantage (MA) Stars ratings and competitive pressures. Additionally, the risks associated with increased MA utilization, inadequate reimbursement rates, declining membership in prescription drug plans (PDP), and slower growth in healthcare services are significant factors contributing to the company's uncertain future performance. Furthermore, management anticipates that investments required to support Stars recovery could lead to a potential shortfall of approximately 10% in fiscal year 2027 EPS estimates, highlighting the financial strain that may affect Humana's profitability.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares